FDA Approves Zynyz as Initial Therapy for Advanced Anal Cancer

The U.S. Food and Drug Administration (FDA) has granted approval for Zynyz (retifanlimab-dlwr), marking it as the first-line treatment option for advanced anal cancer. This humanized monoclonal antibody is designated for use in combination with carboplatin and paclitaxel, a form of platinum-based chemotherapy, specifically for adults diagnosed with inoperable, locally recurrent, or metastatic squamous cell carcinoma of the anal canal (SCAC).

In addition to its combination therapy, Zynyz has also received approval as a standalone treatment for patients experiencing disease progression while on, or who are intolerant to, platinum-based chemotherapy.

The FDA's decision is grounded in the findings from the phase 3 POD1UM-303/InterAACT2 clinical trial, which demonstrated a significant 37% reduction in the risk of disease progression or death among patients treated with Zynyz combined with chemotherapy, compared to those receiving a placebo. Furthermore, patients in the Zynyz group enjoyed a longer median progression-free survival of 9.3 months, compared to 7.4 months for the placebo group. An interim analysis also revealed a 6.2-month increase in median overall survival.

Despite its efficacy, the treatment is not without risks. Serious adverse reactions were reported in 47% of patients receiving Zynyz alongside chemotherapy. The most common complications included sepsis and pulmonary embolism, each occurring in 3.2% of patients, as well as diarrhea and vomiting, both affecting 2.6% of participants.

There is a growing recognition of the challenges faced by anal cancer patients, who often encounter significant stigma and a lack of public understanding regarding the disease's risk factors and symptoms. The approval of Zynyz is seen as a pivotal advancement in the treatment landscape for advanced SCAC, providing much-needed options for those whose condition has recurred or metastasized.

This milestone was achieved under the auspices of Incyte, the pharmaceutical company behind Zynyz.